Exodus Technology Overview
Nano Painkiller offers Focus Pain Ablation (FPA) technology as a groundbreaking, non-drug solution for targeted, permanent chronic pain relief. This innovation addresses the massive global health and economic burden of chronic pain, which affects approximately 20% of the adult Western population and fuels a global drug market valued at $78.41 billion in 2022. The critical need for alternatives stems from the opioid crisis, which has resulted in addiction, overdoses, and deaths, highlighting the failures and risks of current systemic drug therapies. The core technology uses a molecule comprising Gold Nanoparticles (AuNP), conjugated with a neuronal tracer. This molecule is injected into the painful area and transported retrogradely along the nerve axon to the sensory nerve cell body located in the Dorsal Root Ganglion (DRG). External Ultrasound (US) energy is then applied to the DRG to activate the nanoparticles, causing localized destruction of the specific cell body and silencing the pain signal. This two-stage selectivity ensures that motor nerves are not affected. The primary business opportunity lies in replacing repeat-intensive procedures and long-term drug dependence with a permanent solution. The initial application targets Knee Osteoarthritis Pain, a condition affecting 300 million people worldwide and valued at $6.76 billion. Compared to current Radiofrequency Ablation (RFA), FPA offers a longer-lasting effect because ablating the DRG cell body prevents nerve regrowth, thereby eliminating the need for repeating treatment every 3–6 months.
Cumulative Funding Raised Over Time ($)
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $150K |
| Last funding | $150K |
| Stage | Pre-Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | nano-pk.com |
Locations
Harimon St 4, Giv'at Shmuel, Israel
Photos & Videos
1 item(s)
Exodus Technology Business
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsProvidersCore Technology
Materials & SubstancesNanomaterialsBiologicalsTags (4)
medical-deviceschronic-painbiotechnologynanotechnologyGeographic Markets
AsiaNorth AmericaEuropeExodus Technology Financials
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Exodus Technology Lifecycle
Cumulative Funding Raised Over Time
All Events
Exodus Technology News
0 articlesNo news articles.
Exodus Technology Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Exodus Technology Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 80/100 |
| Missing | sector, news, markets, external profiles, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 517128161 |
| Phone | 0508807135 |
| Creator | Michael Zilbershlag |
| Creator email | michael.zilbershlag@gmail.com |
| Last update | 2025-10-28T00:00:00.000Z |
| Created | 2025-10-28T00:00:00.000Z |
| Claimed | Yes |